首页 > 最新文献

Medicamentos de actualidad. Drugs of today最新文献

英文 中文
New product intros [diclofenac etalhyaluronate, emitasvir phosphate, [18F]fluoroestradiol, furmonertinib mesilate, idecabtagene vicleucel, lisocabtagene maraleucel, naxitamab, pabinafusp alfa, pamiparib, piflufolastat F18, rilonacept (new indication), sotrovimab, viloxazine hydrochloride (new indica 新产品条目[双氯芬酸依他亚糖醛酸酯、磷酸埃米他司韦、[18F]氟雌二醇、甲磺酸弗莫内替尼、依卡他定、利索卡布他定、马拉亮氨酸、纳西塔单抗、帕那福司阿法、帕帕尼、吡氟福司他F18、利乐那cept（新适应症）、索特罗维单抗、盐酸维洛嗪（新适应证）
Medicamentos de actualidad. Drugs of today
Pub Date : 2021-01-01 DOI: 10.1358/dot.2021.57.7.3333207
{"title":"New product intros [diclofenac etalhyaluronate, emitasvir phosphate, [18F]fluoroestradiol, furmonertinib mesilate, idecabtagene vicleucel, lisocabtagene maraleucel, naxitamab, pabinafusp alfa, pamiparib, piflufolastat F18, rilonacept (new indication), sotrovimab, viloxazine hydrochloride (new indica","authors":"","doi":"10.1358/dot.2021.57.7.3333207","DOIUrl":"https://doi.org/10.1358/dot.2021.57.7.3333207","url":null,"abstract":"","PeriodicalId":85144,"journal":{"name":"Medicamentos de actualidad. Drugs of today","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66458729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New product intros [aducanumab-avwa, aviptadil, belumosudil mesylate, belzutifan (first-in-class), disitamab vedotin, dostarlimab-gxly, fuzuloparib, hetrombopag olamine, ibrexafungerp, imeglimin hydrochloride (first-in-class), infigratinib, Kconvac] 新产品简介[aducanumab-avwa、阿维普地尔、甲磺酸贝鲁莫地尔、贝珠替凡（同类第一）、地西塔单抗韦多汀、多司他利单抗gxly、福祖洛帕利、hetrombopag-alcamin、ibrexafungerp、盐酸伊美格列明（同类第一
Medicamentos de actualidad. Drugs of today
Pub Date : 2021-01-01 DOI: 10.1358/dot.2021.57.10.3369187
{"title":"New product intros [aducanumab-avwa, aviptadil, belumosudil mesylate, belzutifan (first-in-class), disitamab vedotin, dostarlimab-gxly, fuzuloparib, hetrombopag olamine, ibrexafungerp, imeglimin hydrochloride (first-in-class), infigratinib, Kconvac]","authors":"","doi":"10.1358/dot.2021.57.10.3369187","DOIUrl":"https://doi.org/10.1358/dot.2021.57.10.3369187","url":null,"abstract":"","PeriodicalId":85144,"journal":{"name":"Medicamentos de actualidad. Drugs of today","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66458760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New product intros [Ad5-nCoV, COVID-19 inactivated vaccine (WIV04 strain), Ebola virus vaccine (rVSV-EBOV, live), JNJ-78436735, lonafarnib, margetuximab, romiplostim (new indication), tenapanor (first-in-class), tirbanibulin, tocilizumab (new indication), trilaciclib hydrochloride, ZF-2001] 新产品简介[Ad5-nCoV，新冠肺炎灭活疫苗（WIV04株），埃博拉病毒疫苗（rVSV-EBOV，活疫苗），JNJ-78436735，洛那法尼，马吉妥昔单抗，罗普司汀（新适应症），tenapanor（一级），替巴尼布林，托西珠单抗（新适应证），盐酸三唑昔单抗，ZF-2001]
Medicamentos de actualidad. Drugs of today
Pub Date : 2021-01-01 DOI: 10.1358/DOT.2021.57.4.3295638
A. Babu
{"title":"New product intros [Ad5-nCoV, COVID-19 inactivated vaccine (WIV04 strain), Ebola virus vaccine (rVSV-EBOV, live), JNJ-78436735, lonafarnib, margetuximab, romiplostim (new indication), tenapanor (first-in-class), tirbanibulin, tocilizumab (new indication), trilaciclib hydrochloride, ZF-2001]","authors":"A. Babu","doi":"10.1358/DOT.2021.57.4.3295638","DOIUrl":"https://doi.org/10.1358/DOT.2021.57.4.3295638","url":null,"abstract":"","PeriodicalId":85144,"journal":{"name":"Medicamentos de actualidad. Drugs of today","volume":"57 1","pages":"303"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66459036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New product intros [amivantamab-vmjw, anifrolumab-fnia (first-in-class), asciminib, atogepant, avalglucosidase alfa-ngpt, bimekizumab, clascoterone, donafenib, lonapegsomatropin-tcgd, mobocertinib, samidorphan/olanzapine (new combination), teserpaturev, tisotumab vedotin (first-in-class), vosoritide 新产品条目[阿米万塔单抗vmjw、阿尼福鲁单抗fnia（同类第一）、ascimib、阿托格潘、阿伐葡糖苷酶alfa ngpt、比美基珠单抗、克拉斯科酮、多纳非尼、洛那培生长激素tcgd、莫博替尼、氨基多芬/奥氮平（新组合）
Medicamentos de actualidad. Drugs of today
Pub Date : 2021-01-01 DOI: 10.1358/dot.2021.57.12.3388997
{"title":"New product intros [amivantamab-vmjw, anifrolumab-fnia (first-in-class), asciminib, atogepant, avalglucosidase alfa-ngpt, bimekizumab, clascoterone, donafenib, lonapegsomatropin-tcgd, mobocertinib, samidorphan/olanzapine (new combination), teserpaturev, tisotumab vedotin (first-in-class), vosoritide","authors":"","doi":"10.1358/dot.2021.57.12.3388997","DOIUrl":"https://doi.org/10.1358/dot.2021.57.12.3388997","url":null,"abstract":"","PeriodicalId":85144,"journal":{"name":"Medicamentos de actualidad. Drugs of today","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66458911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New product intros [ADV-7103 (new combination), asparaginase Erwinia chrysanthemi, empagliflozin (new indication), MVC-COV-1901, ON-101, penpulimab, ponesimod, sotorasib, upacicalcet sodium hydrate, upadacitinib tartrate (new indication), zimberelimab, ZyCoV-D] 新产品介绍[ADV-7103(新组合)，菊Erwinia，恩格列净(新适应症)，MVC-COV-1901, ON-101，彭普利单抗，ponesimod, sotorasib, upacicalcet sodium hydrate, upadacitinib酒石酸盐(新适应症)，zimberelimab, ZyCoV-D]
Medicamentos de actualidad. Drugs of today
Pub Date : 2021-01-01 DOI: 10.1358/dot.2021.57.11.3381582
{"title":"New product intros [ADV-7103 (new combination), asparaginase Erwinia chrysanthemi, empagliflozin (new indication), MVC-COV-1901, ON-101, penpulimab, ponesimod, sotorasib, upacicalcet sodium hydrate, upadacitinib tartrate (new indication), zimberelimab, ZyCoV-D]","authors":"","doi":"10.1358/dot.2021.57.11.3381582","DOIUrl":"https://doi.org/10.1358/dot.2021.57.11.3381582","url":null,"abstract":"","PeriodicalId":85144,"journal":{"name":"Medicamentos de actualidad. Drugs of today","volume":"50 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66458810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New product intros [anamorelin hydrochloride, casimersen, loncastuximab tesirine, dapagliflozin (new indication), molidustat sodium, mometasone furoate/azelastine hydrochloride (new combination), OTL-200, setmelanotide, umbralisib tosylate (first-in-class), vericiguat] 新产品介绍[盐酸阿那莫瑞林、卡西莫森、loncastuximab tesirine、达格列净(新适应症)、莫度他钠、糠酸莫米松/盐酸氮唑来汀(新组合)、OTL-200、setmelanotide、umbralisib tosylate(同类首创)、vericiguat]
Medicamentos de actualidad. Drugs of today
Pub Date : 2021-01-01 DOI: 10.1358/dot.2021.57.6.3317998
{"title":"New product intros [anamorelin hydrochloride, casimersen, loncastuximab tesirine, dapagliflozin (new indication), molidustat sodium, mometasone furoate/azelastine hydrochloride (new combination), OTL-200, setmelanotide, umbralisib tosylate (first-in-class), vericiguat]","authors":"","doi":"10.1358/dot.2021.57.6.3317998","DOIUrl":"https://doi.org/10.1358/dot.2021.57.6.3317998","url":null,"abstract":"","PeriodicalId":85144,"journal":{"name":"Medicamentos de actualidad. Drugs of today","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66458609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New product intros [coblopasvir dihydrochloride, dasiglucagon, 2-deoxyglucose, estetrol/drospirenone (new combination), risperidone microspheres (new formulation), SaNOtize nitric oxide nasal spray (NONS), tocilizumab (new indication)] 新产品介绍[盐酸哥洛帕韦、地糖卢agon、2-脱氧葡萄糖、esteol /drospirenone(新组合)、利培酮微球(新配方)、sanoize一氧化氮鼻喷雾剂(NONS)、托珠单抗(新适应症)]
Medicamentos de actualidad. Drugs of today
Pub Date : 2021-01-01 DOI: 10.1358/dot.2021.57.8.3341558
{"title":"New product intros [coblopasvir dihydrochloride, dasiglucagon, 2-deoxyglucose, estetrol/drospirenone (new combination), risperidone microspheres (new formulation), SaNOtize nitric oxide nasal spray (NONS), tocilizumab (new indication)]","authors":"","doi":"10.1358/dot.2021.57.8.3341558","DOIUrl":"https://doi.org/10.1358/dot.2021.57.8.3341558","url":null,"abstract":"","PeriodicalId":85144,"journal":{"name":"Medicamentos de actualidad. Drugs of today","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66458795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New product intros [ciprofol, EpiVacCorona, imlifidase (first-in-class), melphalan flufenamide hydrochloride] 新产品介绍[环丙酚、依哌柯那、依米利菲酶(同类首创)、盐酸氟非胺美伐兰]
Medicamentos de actualidad. Drugs of today
Pub Date : 2021-01-01 DOI: 10.1358/dot.2021.57.5.3310148
{"title":"New product intros [ciprofol, EpiVacCorona, imlifidase (first-in-class), melphalan flufenamide hydrochloride]","authors":"","doi":"10.1358/dot.2021.57.5.3310148","DOIUrl":"https://doi.org/10.1358/dot.2021.57.5.3310148","url":null,"abstract":"","PeriodicalId":85144,"journal":{"name":"Medicamentos de actualidad. Drugs of today","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66459068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New product intros (adalimumab (new indication), docaravimab and miromavimab, empagliflozin/linagliptin/metformin hydrochloride (new combination), enarodustat, filgotinib, fluticasone propionate/formoterol fumarate/glycopyrronium (new combination), oliceridine, sofpironium bromide, tafasitamab-cxix, 新产品简介（阿达木单抗（新适应症）、多卡韦单抗和莫洛马韦单抗、恩帕列嗪/利格列汀/盐酸二甲双胍（新组合）、埃那罗司他、非戈替尼、丙酸氟替卡松/富马酸福莫特罗/格隆吡隆（新组合，
Medicamentos de actualidad. Drugs of today
Pub Date : 2021-01-01 DOI: 10.1358/dot.2021.57.1.3265445
{"title":"New product intros (adalimumab (new indication), docaravimab and miromavimab, empagliflozin/linagliptin/metformin hydrochloride (new combination), enarodustat, filgotinib, fluticasone propionate/formoterol fumarate/glycopyrronium (new combination), oliceridine, sofpironium bromide, tafasitamab-cxix,","authors":"","doi":"10.1358/dot.2021.57.1.3265445","DOIUrl":"https://doi.org/10.1358/dot.2021.57.1.3265445","url":null,"abstract":"","PeriodicalId":85144,"journal":{"name":"Medicamentos de actualidad. Drugs of today","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66458676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New product intros [berotralstat hydrochloride, cetuximab sarotalocan, daratumumab sc (new indication), eptacog beta, coagulation factor VIIa-jncw, etesevimab, evinacumab-dgnb (first-in-class), human SARS-CoV-2 inactivated vaccine, inclisiran, orelabrutinib, relugolix (new indication), remogliflozin 新产品引入盐酸贝罗司他、西妥昔单抗、达拉单抗sc(新适应症)、eptacog β、凝血因子VIIa-jncw、etesevimab、evinacumab-dgnb(同类首创)、人SARS-CoV-2灭活疫苗、inclisiran、orelabrutinib、relugolix(新适应症)、remgliflozin
Medicamentos de actualidad. Drugs of today
Pub Date : 2021-01-01 DOI: 10.1358/dot.2021.57.3.3285930
{"title":"New product intros [berotralstat hydrochloride, cetuximab sarotalocan, daratumumab sc (new indication), eptacog beta, coagulation factor VIIa-jncw, etesevimab, evinacumab-dgnb (first-in-class), human SARS-CoV-2 inactivated vaccine, inclisiran, orelabrutinib, relugolix (new indication), remogliflozin","authors":"","doi":"10.1358/dot.2021.57.3.3285930","DOIUrl":"https://doi.org/10.1358/dot.2021.57.3.3285930","url":null,"abstract":"","PeriodicalId":85144,"journal":{"name":"Medicamentos de actualidad. Drugs of today","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66458995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
类型
全部 化学•材料 生命科学 医学 物理 工程技术 环境•农林 材料科学 地球科学 法学 管理学 化学 环境科学与生态学 计算机科学 教育学 经济学 农林科学 人文科学 生物学 数学 物理与天体物理 心理学 综合性期刊 其他 工业工程 理学 历史学 农学 文学 信息工程
数据库
全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley
期刊
Medicamentos de actualidad. Drugs of today
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
﹀
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们：info@booksci.cn
Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1